Potential utility of indomethacin in enhancing the leishmanicidal activity of glucantime.
Namazi
M R
MR
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000276:immunology / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005978:Glutathione / Q000187:drug effects*; D006801:Humans; D007213:Indomethacin / Q000276:immunology / Q000627:therapeutic use*; D018664:Interleukin-12 / Q000276:immunology; D007896:Leishmaniasis / Q000188:drug therapy*; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use*; D018417:Th1 Cells / Q000187:drug effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D018664:Interleukin-12; D008536:Meglumine; D000077485:Meglumine Antimoniate; D005978:Glutathione; D007213:Indomethacin